TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25485782

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2/3 h), carboplatin (AUC 5), and bevacizumab (15 mg/kg) administered every 21 days for 6-8 cycles, followed by maintenance therapy with bevacizumab (15 mg/kg) every 21 days for 16 cycles.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and bevacizumab combination therapy.
Number of subjects: 15
Study: 23159169

Group type: EXPERIMENTAL
Intervention: High insertion torque (up to 80 N cm)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (insertion torque between 30 and 45 N cm)
Number of subjects: 102
Study: 21292441

Group type: EXPERIMENTAL
Intervention: Electronic reminders (ERs)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No reminder (controls)
Number of subjects: 125
Study: 19541014

Group type: EXPERIMENTAL
Intervention: 1 microg ACTH test before major abdominal surgery
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 1 microg ACTH test during operation, on first postoperative day, and before discharge
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 1 microg ACTH test
Number of subjects: 77
Study: 17318618

Group type: EXPERIMENTAL
Intervention: Ibuprofen (5%)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Arnica (50 g tincture/100 g, DER 1:20)
Number of subjects: 204
Study: 15614340

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11252073

Group type: EXPERIMENTAL
Intervention: Creatine (CR; 20 g.d‐1, 5 d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (P, maltodextrine)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 11
Study: 9333879

Group type: EXPERIMENTAL
Intervention: Bone mineral density measurements in the forearm of patients with Colles fracture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group without fracture
Number of subjects: 50
Study: 8317641

Group type: EXPERIMENTAL
Intervention: Entonox with 0.2% isoflurane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Entonox
Number of subjects: 18
Study: 3551506

Group type: EXPERIMENTAL
Intervention: Hydrochlorthiazide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30606425

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycophenolate mofetil
Number of subjects: 0
Study: 28746113

Group type: EXPERIMENTAL
Intervention: Hot packs applied for 10 minutes to the lumbar region
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal packs applied for 10 minutes to the lumbar region
Number of subjects: 34
Study: 25387876

Group type: EXPERIMENTAL
Intervention: Group E (escalating voltage: 11.4‐12.0‐13 kV per 1,000 shock waves, 2 Hz)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group C (constant voltage: 13 kV, 3,000 shock waves, 2 Hz)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group E (escalating voltage)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group C (constant voltage)
Number of subjects: 120
Study: 23311647

Group type: EXPERIMENTAL
Intervention: Community-embedded reproductive health interventions (CERCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised controlled study in Managua
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-randomised controlled study in Cochabamba and Cuenca
Number of subjects: 0
Study: 21681167

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19538334

Group type: EXPERIMENTAL
Intervention: Titanium hand-instruments
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ultrasonic device
Number of subjects: 37
Study: 16709303

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 160/4.5 microg, one inhalation, once or twice daily maintenance plus additional doses as needed (1 x SMART or 2 x SMART)
Number of subjects: 465

Group type: COMPARATOR
Intervention: budesonide/formoterol 160/4.5 microg two inhalations twice daily plus formoterol 4.5 microg as needed (2 x 2 FIX + F)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: 2 x SMART
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: 1 x SMART
Number of subjects: 465

Group type: COMPARATOR
Intervention: 2 x 2 FIX + F
Number of subjects: 465
Study: 15290892

Group type: EXPERIMENTAL
Intervention: 5.5 mm sutured corneal incision
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4.0 mm sutureless corneal incision
Number of subjects: 20
Study: 11705850

Group type: EXPERIMENTAL
Intervention: Cisplatin, IFN α‐2b, doxorubicin, and 5‐fluorouracil (PIAF)
Number of subjects: 41
Study: 9356636

Group type: EXPERIMENTAL
Intervention: Ultrasonographic (US) findings
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Computed tomographic (CT) findings
Number of subjects: 64
Study: 7877117

Group type: EXPERIMENTAL
Intervention: Trimipramine monotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trimipramine with adjunct sleep deprivation (SD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trimipramine with adjunct bright light (BL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 42
Study: 3182456

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg x 2 daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pivampicillin (700 mg x 3 daily)
Number of subjects: 84
Study: 29583066

Group type: EXPERIMENTAL
Intervention: Water-soluble chicken egg yolk peptides
Number of subjects: 0
Study: 27869354

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% twice a day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Emedastine difumarate 0.05% twice a day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% four times a day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Artificial tears (control group) 0.5% three times a day
Number of subjects: 80
Study: 26394887

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 23140547

Group type: EXPERIMENTAL
Intervention: Ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 102
Study: 21667009

Group type: EXPERIMENTAL
Intervention: High-intensity rehabilitation programme
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low-intensity rehabilitation programme
Number of subjects: 79
Study: 19886513

Group type: EXPERIMENTAL
Intervention: Weekly folic acid (5,000 or 2,800 microg) plus iron, zinc, and vitamin B-12 for 12 weeks
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Daily folic acid (400 or 200 microg) plus iron, zinc, and vitamin B-12 for 12 weeks
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 459
Study: 16702169

Group type: EXPERIMENTAL
Intervention: Telephone counseling sessions (8 sessions over 3 months)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Printed materials sent to intervention group participants
Number of subjects: 186

Group type: COMPARATOR
Intervention: Outcome assessments only (control group)
Number of subjects: 186
Study: 15585987

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 75

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 75
Study: 11590256

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rh-Epo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early correction of anaemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher Hb levels
Number of subjects: 0
Study: 9217033

Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg per day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg per day
Number of subjects: 91
Study: 7954485

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30
Study: 3064085

Group type: EXPERIMENTAL
Intervention: ZK 93426 (benzodiazepine receptor antagonist with weak inverse agonist properties)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZK 93426
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29637820

Group type: EXPERIMENTAL
Intervention: hUCB‐MSC infusion (4 infusions at a fixed dose of 5 × 10^7) with basic rehabilitation
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.9% normal saline with basic rehabilitation (Control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: hUCB‐MSC infusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Routine MRI exams
Number of subjects: 54
Study: 28675975

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) and intraoperative cell salvage (ICS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intraoperative cell salvage (ICS) only
Number of subjects: 44
Study: 25641606

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day for 14 days coadministered with aspirin 150 mg/day for 6 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day for 14 days with maintenance warfarin (1-10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23052718

Group type: EXPERIMENTAL
Intervention: Short duration panretinal photocoagulation (PRP) (20 milliseconds)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional panretinal photocoagulation (PRP) (100 milliseconds)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional PRP
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Short duration PRP
Number of subjects: 33
Study: 21959614

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 18416081

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus shenqi fuzheng injection
Number of subjects: 126

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 126
Study: 21948041

Group type: EXPERIMENTAL
Intervention: IMB model-based intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 152
Study: 16858933

Group type: EXPERIMENTAL
Intervention: Bedtime calcium supplementation (2 calcium carbonate tablets, 334 mg per tablet)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bedtime calcium supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Post meal calcium supplementation
Number of subjects: 36
Study: 12032788

Group type: EXPERIMENTAL
Intervention: 8 mg/kg loading dose of aminophylline
Number of subjects: 61

Group type: COMPARATOR
Intervention: 6 mg/kg loading dose of aminophylline
Number of subjects: 61
Study: 10212871

Group type: EXPERIMENTAL
Intervention: Percutaneous gastrostomy tube placement
Number of subjects: 105
Study: 8529534

Group type: EXPERIMENTAL
Intervention: Oral nalmefene glucuronide
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 2227078

Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac tromethamine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac tromethamine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 100 mg pethidine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 150487

Group type: EXPERIMENTAL
Intervention: Levamisole (continuous administration for 16 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study: 12207836

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg twice/d) and Vitamin E (100 mg twice/d) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin C and Vitamin E supplementation
Number of subjects: 100
Study: 31502637

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 29571976

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin C plus Vitamin E
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26790705

Group type: EXPERIMENTAL
Intervention: G‐CSF (10 µg/kg for five days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 24886264

Group type: EXPERIMENTAL
Intervention: Proactive telephone peer support (two calls within the first ten days postpartum, then weekly calls until week twelve, with continued contact until six months postpartum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 22325807

Group type: EXPERIMENTAL
Intervention: Positive staff-patient relationships
Number of subjects: 204

Group type: COMPARATOR
Intervention: Neutral staff-patient relationships
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Care co-ordinators with positive relationships
Number of subjects: 204
Study: 20973465

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (Sprinkles) - 60 sachets (12.5 mg elemental iron) taken daily for 2 months
Number of subjects: 2193

Group type: COMPARATOR
Intervention: Control group (no micronutrient powder)
Number of subjects: 2193
Study: 17509150

Group type: EXPERIMENTAL
Intervention: FIT-HaNSA
Number of subjects: 41

Group type: COMPARATOR
Intervention: DASH
Number of subjects: 41

Group type: COMPARATOR
Intervention: SPADI
Number of subjects: 41
Study: 16176737

Group type: EXPERIMENTAL
Intervention: Continence nurse practitioner intervention (8-week primary intervention package including advice on diet and fluids; bladder training; pelvic floor awareness and lifestyle advice)
Number of subjects: 3746

Group type: EXPERIMENTAL
Intervention: Continence nurse practitioner intervention
Number of subjects: 3746

Group type: COMPARATOR
Intervention: Standard care (existing primary care including GP and continence advisory services)
Number of subjects: 3746

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3746
Study: 12534637

Group type: EXPERIMENTAL
Intervention: Aminophylline (mean rate 9.2 +/- 2.6 micro g kg‐1 min‐1)
Number of subjects: 75
Study: 10390684

Group type: EXPERIMENTAL
Intervention: Revised information leaflet
Number of subjects: 235

Group type: COMPARATOR
Intervention: Original information leaflet
Number of subjects: 235
Study: 8888381

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1894824

Group type: EXPERIMENTAL
Intervention: Leadup activity
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no leadup activity)
Number of subjects: 64
Study: 6614417

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 0
Study: 31587722

Group type: EXPERIMENTAL
Intervention: High-fidelity mannequin simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Virtual simulation
Number of subjects: 0
Study: 29560057

Group type: EXPERIMENTAL
Intervention: Baby shampoo (n=21)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Water irrigation (control, n=19)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Baby shampoo (n=10)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Water irrigation (control, n=8)
Number of subjects: 58
Study: 26748101

Group type: EXPERIMENTAL
Intervention: Computer-based intervention (CO)
Number of subjects: 6251

Group type: EXPERIMENTAL
Intervention: In-person intervention (PE)
Number of subjects: 6251
Study: 24894386

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.05 to 0.2 μg.kg⁻¹.min⁻¹ for 24 hours)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo for 24 hours
Number of subjects: 516
Study: 21720841

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 60
Study: 21194606

Group type: EXPERIMENTAL
Intervention: 300-mg test formulation of rifampicin
Number of subjects: 14

Group type: COMPARATOR
Intervention: 150-mg reference formulation of rifampicin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 300-mg test formulation of 25-desacetyl rifampicin
Number of subjects: 14

Group type: COMPARATOR
Intervention: 150-mg reference formulation of 25-desacetyl rifampicin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bioequivalence assessment for rifampicin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bioequivalence assessment for 25-desacetyl rifampicin
Number of subjects: 14
Study: 17606479

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sufentanil TCI
Number of subjects: 40
Study: 16260708

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 0
Study: 11895467

Group type: EXPERIMENTAL
Intervention: Glibenclamide (0.1, 0.3, 1.0 and 3.0 microg min‐1 dL‐1)
Number of subjects: 27
Study: 10197802

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin (AmBisome) 2 mg/kg three times weekly
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 7556234

Group type: EXPERIMENTAL
Intervention: Norfloxacin (200 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2090473

Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Methacholine challenge
Number of subjects: 16
Study: 7420656

Group type: EXPERIMENTAL
Intervention: Computer reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computer reminders with relevant medical literature citations
Number of subjects: 0
Study: 31146330

Group type: EXPERIMENTAL
Intervention: Height-adjustable standing desks for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no standing desks)
Number of subjects: 38
Study: 27994066

Group type: EXPERIMENTAL
Intervention: RT+TMZ
Number of subjects: 196

Group type: COMPARATOR
Intervention: RT+NU
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: IDH1 positive patients
Number of subjects: 196

Group type: COMPARATOR
Intervention: IDH1 negative patients
Number of subjects: 196
Study: 26095068

Group type: EXPERIMENTAL
Intervention: Fermented milk product containing probiotic (FMPP) 65 mL/day for 6 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Open-label FMPP treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Withdrawal phase after open-label FMPP treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both FMPP and placebo
Number of subjects: 45
Study: 24285428

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 360 µg thrice weekly for 8 weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 720 µg thrice weekly for 8 weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 1080 µg thrice weekly for 8 weeks
Number of subjects: 200
Study: 22211999

Group type: EXPERIMENTAL
Intervention: PUVA therapy for 12 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control biopsies from 5 healthy volunteers
Number of subjects: 30
Study: 19384844

Group type: EXPERIMENTAL
Intervention: Minimal CAC (CACS 0 to 30)
Number of subjects: 36

Group type: COMPARATOR
Intervention: High CAC (CACS > 30)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Older patients with CACS progression
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mineral metabolism control
Number of subjects: 36
Study: 17445011

Group type: EXPERIMENTAL
Intervention: Primary PCI for STEMI
Number of subjects: 189
Study: 16234063

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 0
Study: 12518180

Group type: EXPERIMENTAL
Intervention: Nifedipine-GITS
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Felodipine-ER
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 116
Study: 10417626

Group type: EXPERIMENTAL
Intervention: Base cream containing sonicated Streptococcus thermophilus
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Base cream containing purified bacterial neutral sphingomyelinase
Number of subjects: 17

Group type: COMPARATOR
Intervention: Inhibition of bacterial neutral sphingomyelinase activity through glutathione
Number of subjects: 17
Study: 8625149

Group type: EXPERIMENTAL
Intervention: Sandostatin (1 mg every 8 hours for 14 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (16 patients undergoing endoscopic and surgical biopsy)
Number of subjects: 25
Study: 2285172

Group type: EXPERIMENTAL
Intervention: Intervention group (handwashing educational program, use of vinyl gloves, use of disposable diaper changing pads, use of alcohol-based hand rinse)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 7237203

Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 99
Study: 29792087

Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy (ISTDP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 32
Study: 31133219

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) program
Number of subjects: 32
Study: 29091570

Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 110
Study: 27802556

Group type: EXPERIMENTAL
Intervention: Osteopathic Cranial Manipulative Medicine (OCMM)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham therapy (light pressure applied to the cranium)
Number of subjects: 89
Study: 24853043

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM alone for 21 days at a total dose of 2 × 10(10) CFU b.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM in combination with B-LBi07 for 21 days at a total dose of 2 × 10(10) CFU b.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both treatment groups (L-NCFM alone and L-NCFM with B-LBi07)
Number of subjects: 20